New research finds that endothelial TDP-43 loss disrupts the blood-brain barrier, linking vascular dysfunction to Alzheimer’s, ALS and FTD.
For decades, research into neurodegenerative diseases such as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) has focused largely on neuronal dysfunction and protein aggregation. However, new findings from researchers at the University of Connecticut School of Medicine suggest that the integrity of the blood-brain barrier (BBB) may also be a crucial factor in disease progression [1]. Their study, recently published in Nature Neuroscience, identifies a previously unappreciated role for the RNA-binding protein TDP-43 in maintaining endothelial cell function; depletion of TDP-43 in these cells correlates with vascular dysfunction and BBB breakdown across multiple neurodegenerative conditions [1].
Longevity.Technology: The study’s findings on the role of endothelial TDP-43 depletion in disrupting key blood-brain barrier (BBB) pathways in neurodegenerative diseases offer a compelling contribution to the field of geroscience – highlighting the fundamental link between vascular integrity and cognitive longevity. By elucidating how endothelial dysfunction correlates with disease states such as Alzheimer’s, ALS and frontotemporal dementia (FTD), the research advances the argument that cerebrovascular health is not merely a consequence but potentially a driver of neurodegeneration. The identification of a disease-associated subset of capillary endothelial cells presents a common pathway of BBB failure across multiple disorders – suggesting that BBB disruption may be an early and unifying event in neurodegenerative progression.
Crucially, the study’s differentiation between age-related changes and pathological shifts refines our understanding of cognitive decline, reinforcing the necessity of early interventions that target endothelial health to prolong healthspan. Moreover, the application of a novel single-nucleus multiomic approach not only enhances the resolution of cellular alterations but could also set a precedent for future investigations into the molecular interplay between aging, vascular dysfunction and neurodegeneration. From a healthspan perspective, these findings amplify the argument that preserving vascular integrity through targeted therapies – whether by modulating TDP-43 function, fortifying β-catenin signaling or mitigating inflammatory cascades – could prove instrumental in delaying or even preventing the onset of neurodegenerative conditions, thereby extending both lifespan and cognitive vitality.
TDP-43 loss and endothelial dysfunction
TDP-43 is widely recognised for its role in ALS and frontotemporal dementia (FTD), where its aggregation in neuronal cytoplasm is a hallmark of disease pathology. However, evidence is accumulating that TDP-43 dysfunction is not confined to neurons; it is also observed in astrocytes [2], fibroblasts [3] and pancreatic cells [4]. In this latest study, researchers sought to determine whether nuclear levels of TDP-43 are altered in endothelial cells in aging and neurodegenerative diseases, and whether this correlates with BBB disruption.
Using single-nucleus sequencing techniques on postmortem human brain samples from individuals with AD, ALS, FTD and age-matched controls, the researchers identified a disease-associated subset of capillary endothelial cells. These cells exhibited reduced nuclear β-catenin – a critical regulator of BBB integrity – and elevated markers of tumor necrosis factor (TNF) and nuclear factor kappa B (NF-κB) signalling; notably, these transcriptional changes correlated with the depletion of nuclear TDP-43.
The researchers then used experimental models to test whether TDP-43 depletion in endothelial cells could drive these changes; both human and mouse endothelial cells exhibited similar alterations when TDP-43 was depleted, strongly suggesting that endothelial TDP-43 loss contributes directly to BBB dysfunction.
A shift in understanding of blood vessel involvement in neurodegeneration
“It is often said in the field that ‘we are only as old as our arteries’,” says Patrick Murphy, PhD, interim director of the Center for Vascular Biology at UConn School of Medicine. “Across diseases we are learning the importance of the endothelium. I had no doubt the same would be true in neurodegeneration, but seeing what these cells were doing was a critical first step [5].”
This study builds on existing evidence that vascular dysfunction precedes neuronal degeneration in AD and ALS. In AD, BBB breakdown has been observed before the accumulation of amyloid plaques, suggesting that vascular changes may play a causative role rather than being a secondary effect. Similarly, BBB abnormalities have been reported in ALS, though their mechanistic underpinnings have remained unclear.
By pinpointing endothelial TDP-43 depletion as a common feature across multiple neurodegenerative conditions, this study provides a potential unifying mechanism linking vascular dysfunction to neurodegeneration.
Blood vessels as active participants in disease
“It’s easy to think of blood vessels as passive pipelines, but our findings challenge that view,” says Omar Moustafa Fathy, a graduate assistant in the Center for Vascular Biology at UConn School of Medicine. “Across multiple neurodegenerative diseases, we see strikingly similar vascular changes, suggesting that the vasculature isn’t just collateral damage – it’s actively shaping disease progression. Recognizing these commonalities opens the door to new therapeutic possibilities that target the vasculature itself [5].”
One of the key findings from the study is that capillary endothelial cells in AD, ALS and FTD share a distinct transcriptional signature. This includes the suppression of β-catenin signaling – a pathway crucial for maintaining the BBB – and the activation of NF-κB, a pro-inflammatory pathway implicated in a variety of neurodegenerative and vascular conditions [1].
The authors hypothesise that the loss of nuclear TDP-43 disrupts normal endothelial function, shifting these cells towards a pro-inflammatory, barrier-compromised state. This, in turn, may allow toxic proteins, inflammatory mediators and other harmful factors to enter the brain, exacerbating neuronal damage.
Implications for treatment
The findings raise the possibility that stabilising endothelial TDP-43 levels could be a therapeutic strategy to mitigate BBB dysfunction in neurodegenerative diseases. While current treatments for AD and ALS focus primarily on neuronal survival and reducing protein aggregation, targeting the vasculature could provide an alternative approach that addresses disease pathology from a different angle.
Future research will need to explore whether interventions that restore TDP-43 function in endothelial cells can improve BBB integrity and slow neurodegeneration. Additionally, further studies are needed to understand why TDP-43 is lost from endothelial nuclei in the first place – whether due to genetic factors, environmental stressors or other mechanisms.
A broader perspective on neurodegeneration
This study highlights the importance of looking beyond neurons when investigating the causes of neurodegenerative diseases. The brain does not function in isolation – it relies on a complex network of supporting cells, including the vasculature, which may play a more active role in disease than previously assumed.
By identifying a common molecular signature linking vascular dysfunction to neurodegeneration, this research provides new insights into the mechanisms driving AD, ALS and related conditions. As the field moves forward, understanding the interplay between blood vessels and neurons will be critical for developing more effective therapies to combat these devastating diseases.
[1] https://www.nature.com/articles/s41593-025-01914-5
[2] https://pubmed.ncbi.nlm.nih.gov/33127758/
[3] https://www.sciencedirect.com/science/article/abs/pii/S0197458015001098
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC6715357/
[5] https://today.uconn.edu/2025/03/uconn-uncovers-new-clue-on-what-is-leading-to-neurodegenerative-diseases-like-alzheimers-and-als/#
